Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

We are thrilled to share some "Hot off the Press" news that brings a fresh wave of hope to our community. Lantern Pharma and Starlight Therapeutics have just received FDA clearance to begin a Phase 1 clinical trial for a promising new drug combination, STAR-001, specifically for pediatric patients with CNS tumors like ATRT.

What is this trial different?

🧬 The Double-Whammy Strategy: The trial tests a combination of STAR-001 and a common medication called spironolactone.

🧬 The "Synthetic Lethality" Approach: STAR-001 creates damage inside the cancer cell’s DNA. Normally, the cell tries to repair that damage to survive. Spironolactone acts as the "lock," breaking the cell's repair machinery so the cancer cannot fix itself.

🧬 Promising Preclinical Results: In laboratory models of ATRT, this specific combination extended survival by 181% compared to the control groups.

Who is involved?

This trial will be conducted through POETIC, a prestigious consortium of 14 leading children's cancer centers across the US, Canada, and Israel.

What this means for our families

As Lantern Pharma’s CEO, Panna Sharma, put it: For children with relapsed or refractory CNS tumors, the options are desperately limited — and the science behind this planned trial was built to change that."

This milestone represents a genuinely new way to attack these tumors by exploiting their biological vulnerabilities.

Check out the full press release: https://bit.ly/4sNLNqY

"Little Fighters, Big Hope" apparel sale on Bonfire

You can now show your support and help spread awareness by purchasing items from our new collection, including shirts and sweatshirts in a variety of styles and colors!

➡️ Shop the "Little Fighters, Big Hope" collection here: bonfire.com/hope4atrt/

OR, make it personal! If you're looking for a unique way to make an impact, you can also start your own shirt fundraiser! Customize the design with your warrior's name to rally your community and raise even more vital funds.

➡️ Launch your customized fundraiser here: bonfire.com/event/hope4-atrt/

Thank you for being a part of our mission and helping us create a brighter future for children fighting ATRT. Your support makes a world of difference!

ATRT Research Update

Lantern Pharma Inc. (Nasdaq: LTRN)'s drug candidate, LP-184 shows promising in-vivo activity in Atypical Teratoid Rhabdoid Tumors at 2025 Society for Neuro-Oncology Pediatric Conference.

Independent research from Johns Hopkins Medicine, presented by Dr. Eric Raabe at the 2025 SNO Pediatric Neuro-Oncology Conference, supports Lantern’s data that led to their FDA Rare Pediatric Disease Designation and Orphan Drug Designation for LP-184 for the treatment of ATRT.

In-Vivo Data Highlights:

• In-vivo mice models, CHLA06 and BT37, showed survival of increases of 345% and 44% respectively.

• Potent anti-tumor activity across multiple ATRT subtypes (MYC, TYR, SHH)

• Strong blood-brain barrier penetration (Cmax: 730 nM)

• Increased apoptosis(programmed cell death), reduced proliferation in ATRT cancer cells

• Significant survival benefit in two orthotopic xenograft models

• No observed toxicity in vivo

These findings support the planned pediatric clinical trial of LP-184 expected to begin in late 2025 or early 2026.

View the full press release: https://bit.ly/4jrJqF8